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Protein C inhibitor is a member of the serpin family
that inhibits a variety of serine proteases. Protein C
inhibitor is present in numerous body fluids and is
produced in the liver and by various epithelial cells.
To determine if this epithelial serpin is present in skin,
immunohistochemical studies were performed that
showed strong staining for protein C inhibitor antigen
in the epidermis. Protein C inhibitor mRNA was
detected in the keratinocyte cell line HaCaT and the
epidermoid carcinoma cell line A431 using reverse
transcription–polymerase chain reaction suggesting
that also in normal skin protein C inhibitor is derived
from keratinocytes. Conditioned media from these cell
lines were analyzed on immunoblots, which revealed a
protein C inhibitor-antigen band that comigrated with
protein C inhibitor derived from the hepatoma cell
line HepG2. Using an enzyme-linked immunosorbent
assay specific for total protein C inhibitor antigen the
accumulation of protein C inhibitor in the cell culture
Protein C inhibitor (PCI) is a single chain glycoproteinwith a molecular weight of 57 kDa. PCI is a relativelyunspecific, heparin-binding serine protease inhibitor(serpin), originally described in plasma as an inhibitorof the anticoagulant protease activated protein C (Marlar
and Griffin, 1980). Serine proteases inhibited by PCI include
thrombin, factor Xa, factor XIa, tissue and plasma kallikreins,
acrosin, tissue plasminogen activator (tPA), and urokinase (for
review see Suzuki et al, 1989; Geiger et al, 1996, 1997). PCI
antigen is present in various body fluids (Laurell et al, 1992), and
the tubular epithelium of human kidney (Radtke et al, 1994) and
epithelial cells in the male reproductive tract (Laurell et al, 1992)
have been shown to produce PCI. Plasma PCI is thought to be
synthesized in the liver, as the human hepatoma-derived cell line
HepG2 secretes significant amounts of PCI in vitro (Morito et al,
1985; Fair and Marlar, 1986) and as PCI plasma levels are decreased
in patients with liver diseases (Francis and Thomas, 1984).
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supernatants of HaCaT keratinocytes was found to be
0.3 ng per h per 1 million cells. This is similar to the
amount of plasminogen activator inhibitor-1 produced
by these cells, which also produce tissue plasminogen
activator and urokinase. Fluorescence-activated cell
sorter analysis revealed similar expression of intra-
cellular protein C inhibitor antigen in proliferating
and confluent HaCaT cells. These findings demon-
strate that protein C inhibitor antigen is present in the
normal epidermis and that protein C inhibitor is
constitutively expressed by keratinocytes in culture.
Therefore, protein C inhibitor may provide protease
inhibitory activity not only to internal, but also to the
external surface of the body. Additionally, protein C
inhibitor could contribute to the regulation of retinoid
supply in the epidermis, as we have shown recently
that retinoic acid binds specifically to protein C
inhibitor. Key words: epidermis/plasminogen activator
inhibitor/serine protease inhibitor. J Invest Dermatol 113:32–
37, 1999
Plasma PCI is elevated in survivors of myocardial infarction
(Carroll et al, 1997). Activated protein C-PCI complexes have
been shown in plasma samples from patients with disseminated
intravascular coagulation (Espana et al, 1990), and urokinase-PCI
complexes in plasma samples from patients receiving urokinase
therapy (Geiger et al, 1989). These findings suggest that PCI could
play a part in the regulation of hemostasis. Most coagulation and
fibrinolytic enzymes, however, are inactivated more efficiently by
other serpins. Therefore, the precise physiologic role of PCI is
still unclear.
Our group has previously shown that tissue kallikrein is
efficiently inhibited by PCI (Ecke et al, 1992), suggesting that PCI
may be a physiologically important endogenous inhibitor of this
serine protease. Many components of the kallikrein-kinin system
including tissue kallikrein are expressed in human skin, where they
are potentially involved in the regulation of proliferation and in
the mediation of inflammatory processes (Poblete et al, 1991;
Schremmer-Danninger et al, 1995).1,2 So far no epidermal inhibitor
for tissue kallikrein has been described. Furthermore, we have
recently shown that PCI also belongs to the group of hormone-
1Schremmer-Danninger E, Hermann A, Fink E, Fritz H, Roscher AA:
Identification of mRNAs for components of the kallikrein-kinin-system
in human skin and skin diseases. Abstract Book, 15th International Conference
on Kinins-Kinin ‘98 Nara. Nara, Japan, 1998, p 139 (abstr.)
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binding serpins which includes corticosteroid-binding globulin
(Hammond et al, 1987) and thyroxine-binding globulin (Flink et al,
1986): We were able to show that 3H-all-trans-retinoic acid bound
in a concentration-dependent and specific manner to PCI but not
to other inhibitory serpins and binding could be competed by
unlabeled all-trans-retinoic acid, 9-cis-retinoic acid and retinol.
Binding of estradiol, progesterone, testosterone, cortisol, and
aldosterone to PCI was not detected. We have also preliminary
data that PCI might be involved in the delivery of retinoic acid to
target cells.3
The facts that (i) tissue kallikrein is expressed in the epidermis,
that (ii) the epidermis is an important target organ for retinoids
(Fisher and Voorhees, 1996), and that (iii) PCI is expressed in
various kinds of epithelial cells lining internal surfaces, prompted
us to investigate the possible presence of PCI in human skin and
human keratinocyte cell lines. We used the epidermoid cell line
A431 and spontaneously immortalized human keratinocytes
(HaCaT) in these experiments. HaCaT cells maintain full epidermal
differentiation capacity and have been widely used as representative
of normal keratinocytes as they share many features with primary
cells (Boukamp et al, 1988; Reinartz et al, 1994, 1996; Bechtel
et al, 1996; Breitkreutz et al, 1998).
MATERIALS AND METHODS
Immunohistochemistry Normal human trunk skin was obtained from
patients who underwent plastic surgery. The samples were embedded in
Tissue-Tek OCT Compound (Sakura, Tokyo, Japan), snap frozen in liquid
nitrogen, and sectioned at 8 µm thickness using a cryostat. The sections
were mounted on to Histobond microscope slides (Marienfeld, Germany)
and air-dried for 1 h at room temperature. Sections were then fixed for
15 min in 0.5% paraformaldehyde in phosphate-buffered saline (PBS;
2 mmol KH2PO4 per liter , 8 mmol Na2HPO4 per liter, 140 mmol NaCl
per liter, pH 7.4) and permeabilized by sequential treatment with 0.2%
and 1% Triton X-100 in PBS (1 3 10 min each). Slides were then rinsed
with PBS and incubated with 1% bovine serum albumin (BSA; Behring,
Marburg, Germany) in PBS for 30 min. Incubations with 10 µg monoclonal
anti-PCI IgG (4PCI) per ml (Ecke et al, 1992) or nonimmune mouse IgG
diluted in primary antibody diluting buffer (Biomeda, Foster City, CA)
were carried out in a humid chamber at 4°C over night. The slides were
then rinsed with PBS and washed with automation buffer (Biomeda)
(2 3 5 min). Thereafter the slides were treated sequentially with biotinylated
sheep antimouse IgG (Amersham, Little Chalfont, Buckinghamshire, U.K.)
diluted 1:100 in PBS and streptavidin–peroxidase conjugate (Amersham)
diluted 1:300 in PBS. After each incubation step the slides were washed
as described above. Bound peroxidase was visualized using the Liquid
DAB-Plus Substrate Kit (Zymed, San Francisco, CA). Thereafter slides
were washed with distilled water, tissue sections were counterstained
with hematoxylin, rinsed with water, and mounted in Aquatex (Merck,
Darmstadt, Germany). Controls included the substitution of the first
antibody with monoclonal anti-heparin cofactor II IgG, monoclonal anti-
plasminogen activator inhibitor 1 IgG (5PAI) (Technoclone, Vienna,
Austria), and monoclonal anti-complement factor D IgG (D10/4) (Connex,
Martinsried, Germany). Sets of slides were processed together in duplicates.
Cell culture and collection of conditioned media Human hepatoma
cells (HepG2) and the human epidermoid cell line A431 were obtained
from American Type Culture Collection (ATCC; Rockville, MD). The
spontaneously transformed human keratinocyte cell line HaCaT was kindly
provided by Dr. N.E. Fusenig [Deutsches Krebsforschungszentrum (DKFZ),
Heidelberg, Germany] (Boukamp et al, 1988). The cells were grown under
culture conditions (37°C, 5% CO2, 95% air) in Dulbecco’s modified Eagle’s
media (Sigma, St. Louis, MO) containing 10% supplemented calf serum
(Hyclone, Logan, UT), 1 mmol glutamine per liter, and antibiotics (100 µg
streptomycin per ml, 100 IU penicillin per ml, 250 ng amphotericin B per
ml) (all: JHR Biosciences, Lenaxa, KS). The cells received fresh medium
2Hermann A, Kresse H, Neth P, Fink E: Expression of components of the
kallikrein-kinin system in human cell lines. Abstract Book, 15th International
Conference on Kinins-Kinin ‘98 Nara. Nara, Japan, 1998, p 133 (abstr.)
3Jerabek I, Krebs M, Geiger M, Binder BR: Binding and delivery of
retinoic acid by the inhibitory serpin protein C inhibitor (PCI). Abstract
Book, 15th International Conference on Kinins-Kinin ‘98 Nara. Nara, Japan,
1998, p 67 (abstr.)
every 3 d and were subcultured using a split ratio of 1:5 as soon as they
reached confluence. Cells were either grown in 75 cm2 tissue culture flasks
(Iwaki, Japan) in 10 ml medium or in six-well plates (Iwaki) in 2 ml
medium per well. After reaching confluence the monolayers were washed
twice with Hanks’ balanced salt solution (Sigma) and incubated in serum
free medium supplemented with 0.5% BSA (Sigma). After appropriate
incubation times conditioned media were collected, centrifuged to remove
cell debris, and stored at –70°C until analyzed.
RNA preparation and reverse transcription coupled to polymerase
chain reaction Cells were grown to confluence in 75 cm2 tissue culture
flasks, washed twice with Hanks’ balanced salt solution (Sigma), and total
cellular RNA was isolated using Trizol reagent (Gibco, Grand Island, NY)
according to the manufacturer’s instructions. Total RNA was subjected to
reverse transcription and subsequent polymerase chain amplification to
show the presence of PCI mRNA in analyzed cells. For reverse transcription
1 µg of total RNA from HaCaT and A431 cells and 0.2 µg or 0.1 µg of
total RNA from HepG2 cells were used. The RNA was preheated at
65°C for 15 min to remove possible secondary structures and then
cooled down to 4°C. Reverse transcription reaction was made using a
first-strand cDNA synthesis kit for reverse transcription–polymerase chain
reaction (Boehringer Mannheim, Mannheim, Germany) at 42°C for 60 min.
Following components were included: an anti-sense human PCI sequence
specific primer 59-CCT GTT GAA CAC TAG CCT CTG AGA G-39 at
final concentration of 0.2 µmol per liter, 50 mmol Tris–HCl buffer per liter,
pH 9.0, 1.5 mmol MgCl2 per liter, 0.2 mmol of each deoxyribonucleoside
triphosphate per liter, 50 U of RNase inhibitor, and 20 U of avian
myeloblastosis virus–reverse transcriptase. Subsequently, 10 µl of the
reaction mixture were taken and after addition of a sense human PCI
sequence specific primer 59-GGA TCA GTA TCA CTA CCT CCT GGA
C-39, polymerase, and other components, the reaction mixture contained
50 mmol Tris–HCl buffer per liter, pH 9.0, 1.5 mmol MgCl2 per liter,
0.2 mmol of each deoxyribonucleoside triphosphate per liter, 0.2 µmol of
each primer per liter, and 1.0 U of DNA polymerase (Dynazyme; Finnzymes
Oy, Finland) in a total volume of 25 µl. The mixture was predenaturated
for 2 min at 94°C and then subjected to 35 step cycles of 94°C (35 s),
58°C (30 s), 72°C (20 s). Amplified DNA fragments exhibited the expected
size (442 base pairs) as judged from 1% agarose gel electrophoresis. Their
identities were confirmed by sequencing.
Immunoblotting of conditioned media Prior to electrophoresis
samples from keratinocytes and HepG2 cells were concentrated and
partially purified by affinity chromatography on heparin-Sepharose CL-6B
(Pharmacia, Uppsala, Sweden). Ten milliliters of conditioned media from
HaCaT, A431, or HepG2 cells, respectively, grown in 75 cm2 tissue culture
flasks were incubated with 0.5 ml heparin-Sepharose equilibrated in 50 mM
Tris–HCl, 100 mM NaCl, pH 7.5 (loading buffer) for 1 h at room
temperature under constant shaking. The Sepharose was filled in a small
column and washed with loading buffer. Thereafter bound protein was
eluted with 1 ml 1 M NaCl in loading buffer. The samples were
concentrated to 100 µl using a 10 kDa molecular weight cut-off Ultra
Spin Microfilter (Roth, Karlsruhe, Germany), electrophoresed on a 10%
sodium dodecyl sulfate–polyacrylamide gel, and electrophoretically trans-
ferred to a Hybond-P PVDF membrane (Amersham) using standard
protocols. The membrane was blocked with 1.5% skim milk powder in
0.02 mol Tris–HCl per liter, 0.5 mol NaCl per liter, pH 7.5 (blocking
buffer) over night at 4°C followed by a 2 h incubation with 10 µg per ml
of specific rabbit anti-PCI IgG diluted in blocking buffer. The antibody
used was prepared following standard protocols by immunizing a New
Zealand white rabbit with highly purified urinary PCI (Ecke et al,
1992). The blot was washed with 0.02 mol Tris–HCl per liter, 0.5 mol
NaCl per liter, pH 7.5, containing 0.05% Tween 20 (3 3 5 min) and
twice with the same buffer without Tween 20 followed by a 1 h incubation
with peroxidase linked anti-rabbit IgG (Amersham, Little Chalfont,
Buckinghamshire, UK) diluted 1:1000 in blocking buffer. The membrane
was washed as described and bound peroxidase was detected using
chemiluminescence (ECL; Amersham). Prestained sodium dodecyl sulfate-
standards (BioRad, Richmond, CA) were used for estimation of Mrs.
Quantitation of PCI antigen in conditioned media PCI antigen in
the conditioned media was quantitated by a specific enzyme-linked
immunosorbent assay (ELISA) as described previously (Priglinger et al,
1994), using acid-treated monoclonal anti-PCI IgG (4PCI) as catching
antibody and peroxidase-labeled immunopurified rabbit anti-PCI IgG as
detecting antibody.
Assays for plasminogen activator inhibitor 1 (PAI-1) antigen,
tPA antigen, and urokinase type plasminogen activator (uPA)
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Figure 1. PCI antigen is present in normal human skin. Frozen
sections of normal human skin were stained with monoclonal anti-PCI
IgG (4PCI) (A) or nonimmune mouse IgG (B) as described in Materials
and Methods. Scale bar: 50 µm.
antigen PAI-1 in conditioned media was quantitated by a specific ELISA
based on monoclonal antibodies, which allows determination of active and
latent PAI-1 as well as PAI-1 in complex with tPA (Technoclone, Vienna,
Austria). tPA antigen and uPA antigen were measured with specific
ELISA according to the instruction of the manufacturer (Technoclone,
Vienna, Austria).
Fluorescence-activated cell sorter (FACS) analysis HaCaT cells
were grown in six-well plates in Dulbecco’s modified Eagle’s media
supplemented with 10% supplemented calf serum. Forty-eight hours after
reaching confluence the cells were harvested with trypsin-ethylenediamine
tetraacetic acid, washed with PBS, pH 7.4, and centrifuged at 450 3 g for
5 min. Alternatively, HaCaT cells were seeded at low concentrations to
obtain scattered single cells, incubated for 48 h in Dulbecco’s minimal
essential media containing 10% supplemented calf serum, and trypsinized
as described above. One-half of the pelleted cells was fixed with 0.5%
paraformaldehyde in PBS, permeabilized with 0.025% saponin (Sigma) in
PBS. The other half was used unpermeabilized. Unspecific binding sites
were blocked by incubating the cells with 1% BSA in PBS. Thereafter
cells were washed with PBS, pH 7.4, containing 1% BSA and 0.025%
saponin and centrifuged at 450 3 g for 5 min. Subsequently cells were
incubated with rabbit anti-PCI IgG at a concentration of 20 µg per ml in
PBS containing 1% BSA and 0.025% saponin for 2 h at room temperature.
After washing as described above the cells were incubated with fluorescein-
labeled goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA) diluted
1:50 in PBS containing 1% BSA and 0.025% saponin. Control cells were
only incubated with the fluorescein-labeled antibody. Then the cells were
washed once as described above and once with PBS, pH 7.4. Analysis was
performed by a FACS Scan flow cytometer using CellQuest 3.1 software
(Becton Dickinson, San Jose, CA).
RESULTS
An immunohistochemical analysis with monoclonal anti-PCI IgG
was performed to determine whether or not PCI is present in
normal adult skin. Pronounced uniform staining for PCI antigen was
detected in the keratinocytes throughout the epidermis (Fig 1A). In
control sections stained with nonimmune mouse IgG (Fig 1B) and
monoclonal antibodies to heparin cofactor II, plasminogen activator
inhibitor 1 (PAI-1), or complement factor D no signal was observed
(data not shown). In situ hybridization studies using specific sense
Figure 2. HaCaT, A431, and HepG2 cells produce PCI mRNA.
Total RNA obtained from HaCaT (1 µg, lane B), A431 (1 µg, lane C),
and HepG2 (0.2 µg, lane D and 0.1 µg, lane E) cells was subjected to
reverse transcription–polymerase chain reaction using primers specific for
a 442 bp fragment of PCI-cDNA as described in Materials and Methods.
The fragments obtained were loaded on a 1% agarose gel and visualized
after electrophoresis by ethidium bromide staining. The control in lane F
is a template free reaction. Lane A contains molecular weight markers
(λEcoRI–HindIII digest).
and anti-sense digoxigenin labeled RNA-probes for PCI were
performed. No PCI mRNA was apparent in human skin (data not
shown), however, presumably because the method was not sensitive
enough to detect the low levels of PCI mRNA present in normal
keratinocytes (see below).
In order to confirm the results obtained with the immunohisto-
chemical studies of normal skin, PCI synthesis by keratinocytes was
analyzed. PCI mRNA expression in spontaneously immortalized
human keratinocytes (HaCaT) and epidermoid carcinoma cells
(A431) was analyzed using reverse transcription–polymerase chain
reaction. RNA prepared from human hepatoma cells (HepG2) was
used as a positive control. Figure 2 demonstrates that PCI mRNA
was present in all three cell lines. A strong signal, that was dependent
on the amount of RNA used, was obtained with HepG2 cells. In
RNA prepared from A431 cells a pronounced band for PCI
mRNA was detected, whereas the signal for PCI mRNA in HaCaT
cells was rather weak.
To determine whether the PCI mRNA produced in these cells
is translated and the protein is secreted into the supernatant,
conditioned media were analyzed in immunoblots and ELISA.
Figure 3 demonstrates that PCI antigen accumulated over time in
the cell culture supernatants from HaCaT, A431, and HepG2 cells.
PCI in conditioned media was partially purified and concentrated
using heparin-Sepharose and analyzed in immunoblots (Fig 3A),
developed with specific polyclonal antibodies. These blots revealed
a protein band with a Mr of µ60 kDa in the conditioned media
of HaCaT and A431 cells, which comigrated with PCI derived
from HepG2 cells. Specificity of the reactions was validated with
control blots incubated only with the second, peroxidase-labeled
antibody. No bands were detected in these blots (data not shown).
The amount of PCI obtained from conditioned media of A431
and HepG2 cells was much higher than that of HaCaT cells,
reflecting the rate of PCI secretion. These data were confirmed by
a specific antigen ELISA (Fig 3B), showing that PCI antigen
accumulated much faster in the supernatants from A431 and HepG2
as compared with HaCaT cells. The concentrations of PCI antigen
in conditioned media of HaCaT, A431, and HepG2 cells were
33 ng per ml, 475 ng per ml, and 650 ng per ml, respectively, after
a conditioning time of 24 h.
The accumulation of PCI was compared with that of uPA, tPA,
and PAI-1 in conditioned media of HaCaT cells. Figure 4,
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Figure 3. (A) PCI antigen is present in
conditioned media from keratino-
cytes. Conditioned media from HaCaT
(lanes A and B) and A431 (lanes C and D)
cells were collected after incubation times
of 24 h (lanes A and C) or 48 h (lanes B
and D). Conditioned media (24 h) from
HepG2 cells (lane E) were used as positive
control. The samples were run on a 10%
sodium dodecyl sulfate–polyacrylamide gel
and transferred on to a PVDF membrane.
Rabbit anti-PCI IgG and peroxidase linked
anti-rabbit antibodies were used to
identify PCI related protein bands as
described in Materials and Methods. (B) PCI
antigen accumulates in conditioned
media of HaCaT, A431, and HepG2
cells. Conditioned media were collected
from confluent monolayers after incubation
times of 4, 8, and 24 h and PCI antigen
was determined by a specific ELISA. Data
presented are the mean values of two
determinations.
demonstrates that the secretion rates of the serpins (PCI and
PAI-1) were similar (approximately 0.3 ng per h per 1 million
cells), whereas considerably more uPA than tPA was produced.
FACS analysis was used to compare the expression of intracellular
PCI antigen in proliferating and confluent HaCaT cells. As can be
seen from Fig 5, no difference in PCI antigen between proliferating
and nonproliferating cells was observed. The PCI detected in this
assay was located mainly intracellularly as only a weak signal for
PCI antigen was observed in nonpermeabilized cells.
DISCUSSION
In the present study we have shown that PCI is present in normal
human epidermis and that PCI mRNA and antigen are expressed
by cultured keratinocytes. The immunohistochemical localization
experiments for PCI revealed that PCI was expressed in the basal,
proliferating as well as in the more superficial, differentiating
keratinocytes of the epidermis. The notion that PCI is constitutively
expressed by keratinocytes is supported by the FACS data showing
that intracellular PCI is equally present in proliferating and
confluent, growth arrested HaCaT.
It has been shown that keratinocytes can produce the plasminogen
activators uPA and tPA as well as the plasminogen activator
inhibitors PAI-1 and PAI-2 in culture and that the pattern of
expression of these proteins depends on the state of differentiation
(Jensen et al, 1990, 1995; Chen et al, 1993; Reinartz et al, 1996).
HaCaT cells secrete twice as much PAI-2 into the supernatant as
compared with PAI-1 (Reinartz et al, 1996). This is in accordance
to previous studies showing that in contrast to PAI-1, PAI-2 can
be detected in normal epidermis by mRNA, antigen, and activity
assays (Lyons-Giordano et al, 1994). These results indicate that
PAI-2 (for review see Belin, 1993) is the predominant PAI in
keratinocytes in vivo as well as in vitro (Jensen et al, 1995). The
distribution of PCI in the epidermis is similar to that of PAI-2:
PAI-2 mRNA and antigen have been detected throughout the
epidermis, whereas PAI-1 was localized predominantly to the
keratinocytes of the basal layer (Chen et al, 1993; Lyons-Giordano
et al, 1994). Receptor-bound urokinase is thought to play an
important part in proliferation and differentiation of keratino-
cytes (Reinartz et al, 1994), and PAI-2 has been implicated in the
regulation of uPA activity in the epidermis (Reinartz et al,
1996). The second order rate constants for the interaction of PCI
with urokinase (1–8 3 103 per M per s without heparin and
4 3 103–9 3 104 per M per s with heparin) are much lower than
those for the interaction of urokinase with PAI-1 (.107 per M
per s) or PAI-2 (2 3 106 per M per s) (Thorsen et al, 1988; Geiger
et al, 1989). Therefore, it is unlikely that PCI plays a major part in
the regulation of epidermal urokinase activity.
It has been postulated that keratinocytes elaborate pro-
Figure 4. HaCaT cells secrete uPA, tPA, and similar amounts of
PCI and PAI-1. Conditioned media were collected from confluent
monolayers after incubation times of 4, 8, and 24 h and the concentrations
of the respective antigens were determined by specific ELISA.
inflammatory mediators including bradykinin in response to diverse
stimuli and thereby initiate cutaneous inflammation (Barker et al,
1991). The main components of the kallikrein–kinin system
(reviewed in Scicli and Carretero, 1986), including tissue kallikrein,
are present in human skin (Poblete et al, 1991). As PCI is a potent
inhibitor of tissue kallikrein (Ecke et al, 1992) and as no other
inhibitor of this serine protease has been described in skin, PCI
might be a physiologically important inhibitor of tissue kallikrein
in the epidermis.
PCI seems to be a protein, associated with internal as well as
external body surfaces, as it has been identified in numerous body
fluids and in various epithelial cells (Laurell et al, 1992; Radtke
et al, 1994). This protease inhibitor is unusual in that it inhibits
chymotrypsin as well as or even better than trypsin, suggesting that
it has a broad reactivity with various serine proteases (Suzuki et al,
1984; Cooper and Church, 1995). It has been suggested that PCI
in the male reproductive tract might function as a scavenger of
prematurely activated acrosin, a serine protease stored as proacrosin
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Figure 5. Proliferating and non-
proliferating HaCaT cells express
similar amounts of intracellular PCI.
PCI antigen was detected in permeabilized
disperse growing and confluent cells using
rabbit anti-PCI IgG (thick line). The thin
line represents the fluorescence of control
cells treated only with the second, fluor-
escein-labeled antibodies. In panel A the
pattern of fluorescence of confluent,
growth arrested cells and in panel B the
intensity of fluorescence of scattered, proli-
ferating cells is shown. The FACS analyzes
for permeabilized cells are shown on the
left and the ones for nonpermeabilized cells
are presented on the right.
in the acrosome of spermatozoa, and thereby protect the male
reproductive system from proteolytic damage by this protease
(Zheng et al, 1994). Similarly PCI might protect other body surfaces
including the skin from proteolysis by providing unspecific protease
inhibitory activity.
PCI is a member of the family of serine protease inhibitors
(serpins) (for review, see Harper and Carrell, 1994). During the
course of evolution, two members of this group, corticosteroid-
binding globulin (Hammond et al, 1987) and thyroxine-binding
globulin (Flink et al, 1986), have apparently exchanged their
proteinase inhibitory properties for a new role as carriers of insoluble
hormones. We have recently shown that all-trans-retinoic acid
bound in a specific and concentration-dependent way to PCI but
not to other serpins, suggesting an additional role of PCI as retinoic
acid delivering serpin.3 The growth and differentiation of the
epidermis and other epithelia is critically dependent upon
undisturbed delivery of retinoids (Fisher et al, 1996).
Therefore epidermal PCI might not only serve as a protease
inhibitor being involved in the regulation of the kallikrein–kinin
system and/or the protection of the skin from various proteases,
but might also take part in the regulation of retinoic acid supply
in the skin.
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